Stockscreener 앱 받기
54.85
1.66%
-0.955
전일 마감가:
$55.80
열려 있는:
$55.04
하루 거래량:
2.42M
Relative Volume:
0.34
시가총액:
$21.77B
수익:
$2.23B
순이익/손실:
$-3.19B
주가수익비율:
-6.7332
EPS:
-8.1462
순현금흐름:
$-1.60B
1주 성능:
-5.49%
1개월 성능:
-21.26%
6개월 성능:
+17.11%
1년 성능:
+68.03%
1일 변동 폭
$54.16
$56.25
1주일 범위
$53.34
$58.43
52주 변동 폭
$22.28
$85.60
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
54.87 | 22.07B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
490.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
696.39 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
880.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
181.60 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.20 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Eversept Partners LP Has $8.11 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Renaissance Technologies LLC Acquires 312,800 Shares of Moderna, Inc. $MRNA - MarketBeat
(MRNA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Moderna (MRNA) Laps the Stock Market: Here's Why - Yahoo Finance Singapore
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? - The Globe and Mail
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? - The Motley Fool
Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA) - Yahoo Finance
Weiss Asset Management LP Has $4.76 Million Position in Moderna, Inc. $MRNA - MarketBeat
Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Moderna stock stays tied to vaccine demand and cash burn - Ad-hoc-news.de
Moderna, Inc. Revenue Breakdown – BX:0QF - TradingView
Moderna Inc (MRNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moderna: A Stock to Watch or a Risky Bet? - The Globe and Mail
Moderna Inc (MRNA) Institutional Confidence - TradingKey
Moderna Inc (MRNA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moderna, Inc. Revenue Breakdown – VIE:MRNA - TradingView
Moderna stock may move 4.2% on July 31 earnings release By Investing.com - Investing.com Nigeria
Moderna stock may move 4.2% on July 31 earnings release - Investing.com
Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Baillie Gifford (MRNA) discloses 18.2M Moderna shares in latest 13G/A - Stock Titan
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance Singapore
Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News - simplywall.st
First Trust Advisors LP Raises Stock Position in Moderna, Inc. $MRNA - MarketBeat
GC Biopharma Files for Phase 2 Trial of Korean-Made mRNA COVID-19 Vaccine, Aiming for August Start - finance.biggo.com
Moderna Inc (MRNA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Moderna (MRNA) Projected to Post Earnings on Friday - MarketBeat
Earnings Preview: What To Expect From Moderna’s Report - Yahoo Finance
Biotech experts want FDA drug reviews based on science, not politics - marketscreener.com
Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Rabies Vaccine Candidate by Moderna Inc.mRNA approach in early trials - AD HOC NEWS
Bank of New York Mellon Corp Reduces Position in Moderna, Inc. $MRNA - MarketBeat
California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA - MarketBeat
Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near? - Yahoo! Finance Canada
Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift - Yahoo Finance
The mRESV by Moderna. An mRNA RSV vaccine candidate for older adults - Ad-hoc-news.de
Moderna stock stabilizes as oncology pipeline and vaccine revenue reshape growth outlook - Ad-hoc-news.de
MRNA Maintained and Target Raised by Goldman Sachs -- Now $67.00 - GuruFocus
Moderna stock outlook: doubled YTD but Wall Street says the easy money is made - Investing.com
Moderna Inc. Stock Slides 3.8%, Underperforms Peers - webull.com
Moderna, Inc. $MRNA Stock Holdings Increased by Fifth Third Bancorp - MarketBeat
Moderna Hits CureVac With Countersuit In COVID Vax Fight - Law360
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? - Yahoo Finance
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo! Finance Canada
Moderna, Inc.'s Stock Price Drops to $59.49, a Decline of 3.77%, Investors Eye Market Performance Closely - Smartkarma
Moderna says CureVac broke agreement by suing over COVID vaccine patents - Reuters
Moderna stock steadies as RSV and COVID vaccine revenues reshape outlook - AD HOC NEWS
Moderna counters CureVac patent lawsuit over Covid-19 vaccines By Investing.com - Investing.com Canada
Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating - marketscreener.com
Wolfe Research raises Moderna stock price target to $25 on updates - Investing.com
D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Encyclopedia Britannica
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Jul 15 '26 |
Sale |
67.60 |
53,336 |
3,605,514 |
1,483,848 |
0.24%
0.61%
자본화:
|
볼륨(24시간):